As AbbVie moved away from promotional spend on its aging megablockbuster Humira at the same time Sanofi and Regeneron stepped up their TV campaigns for Dupixent in 2021, you might be forgiven for ...
Sanofi and Regeneron’s immunology blockbuster Dupixent had been on a mini streak as king of the pharma airwaves but was knocked off its perch in June by AbbVie’s competing drug Rinvoq. That’s ...
AbbVie ABBV announced positive results from its mid-stage study evaluating Rinvoq (upadacitinib) in a new indication. The phase IIb study evaluated the 6 mg, 11 mg and 22 mg dose strengths of Rinvoq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback